CMUAX
Price
$17.74
Change
+$0.16 (+0.91%)
Updated
Sep 11 closing price
Net Assets
3.28B
MVCAX
Price
$34.27
Change
+$0.08 (+0.23%)
Updated
Sep 11 closing price
Net Assets
16.78B
Interact to see
Advertisement

CMUAX vs MVCAX

CMUAX vs MVCAX Comparison Chart in %
View a ticker or compare two or three
VS
CMUAX vs. MVCAX commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMUAX is a Buy and MVCAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
MVCAX has more cash in the bank: 16.8B vs. CMUAX (3.28B). MVCAX pays higher dividends than CMUAX: MVCAX (1.08) vs CMUAX (0.46). CMUAX was incepted earlier than MVCAX: CMUAX (25 years) vs MVCAX (25 years). CMUAX (1.13) is less costly to investors than MVCAX (0.98). MVCAX is a more actively managed with annual turnover of: 24.00 vs. CMUAX (15.00). CMUAX (6%) and MVCAX (6%) have equivalent initial investment costs. MVCAX has a lower initial minimum investment than CMUAX: MVCAX (1000) vs CMUAX (2000). CMUAX annual gain was more profitable for investors over the last year : 18.71 vs. MVCAX (5.51). CMUAX return over 5 years is better than : 35.82 vs. MVCAX (15.15).
CMUAXMVCAXCMUAX / MVCAX
Total Expense Ratio1.130.97116%
Annual Report Gross Expense Ratio1.130.98115%
Fund Existence25 years25 years-
Gain YTD20.92112.903162%
Front Load6%6%100%
Min. Initial Investment20001000200%
Min. Initial Investment IRAN/AN/A-
Net Assets3.28B16.8B20%
Annual Yield % from dividends0.461.0842%
Returns for 1 year18.715.51340%
Returns for 3 years49.0223.61208%
Returns for 5 years35.8215.15237%
Returns for 10 years29.4783.4635%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RIOT21.470.52
+2.48%
Riot Platforms
MQ16.330.17
+1.08%
Marqeta Inc
ZIONP17.930.11
+0.62%
Zions Bancorporation NA
VMD8.790.04
+0.46%
Viemed Healthcare
EDSA4.23-0.43
-9.23%
Edesa Biotech